Type 2 Diabetes
Conditions
Brief summary
The purpose of this study is to evaluate the influence of HRS9531 injection on pharmacokinetics of metformin in healthy subjects.
Interventions
HRS9531 injection single dose.
Metformin Hydrochloride tablets 500mg.
Sponsors
Fujian Shengdi Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent; 2. Male subjects aged 18-45 years on the date of signing informed consent (inclusive); 3. Body weight ≥50 kg, body mass index (BMI) within the range of 20.0-30.0 kg/m2 (inclusive); 4. HbA1c\<6.0%.
Exclusion criteria
1. Chronic or severe medical history of the respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, mental system, etc., or those with existing systemic diseases mentioned above, and judged by the investigator to be unsuitable to participate in this study; 2. Obvious gastric emptying abnormalities or gastrointestinal diseases in the past, or had undergone gastrointestinal surgery (except for gastrointestinal polyps, appendix, and haemorrhoidectomy) 3. Past history or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2), a history of pancreatitis or symptomatic gallbladder stones; 4. Surgery within 6 months prior to dosing, planned to undergo surgery during the study period; 5. Participation in clinical trials of any drug or medical device in the 3 months or 5 half-lives, whichever longer, prior to dosing; 6. Blood donation history or blood loss ≥400 mL within 3 months or ≥200 mL within 1 month before dosing, or received blood transfusion within 3 months before dosing; 7. Allergic constitution includes severe drug allergy or history of drug allergy; 8. Hepatitis B surface antigen (HBsAg), HIV antibody, hepatitis C virus antibody (HCVAb), treponema pallidum specific antibody detection, positive; 9. Abnormal laboratory test results or abnormal examinations considered unsuitable to participate in this trial; 10. History of hypoglycaemia; 11. The investigator considers that the subject has any other factors that would make it inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the concentration versus time curve (AUC) of metformin from dosing time (0) to tau (dosing interval) (AUCtau) after 3.5 days. | Start of treatment up to 12 hours. |
Secondary
| Measure | Time frame |
|---|---|
| Maximum concentration (Cmax) of metformin after 3.5 days of treatment. | Start of Treatment up to 30 hours. |
| Area under the concentration versus time curve of metformin from 0 to the time of the last measurable (positive) concentration (AUC0-t) after 3.5 days of treatment. | Start of Treatment up to 30 hours. |
| Area under the concentration versus time curve of metformin from 0 to infinity (AUC0-inf) after 3.5 days of treatment. | Start of Treatment up to 30 hours. |
| Terminal half-life (t1/2) of metformin after 3.5 days of treatment. | Start of Treatment up to 30 hours. |
| Clearance (CL/F) of metformin after 3.5 days of treatment. | Start of Treatment up to 30 hours. |
| Apparent volume of distribution (VzF) of metformin after 3.5 days of treatment. | Start of Treatment up to 30 hours. |
| Time to maximum concentration (Tmax) of HRS9531. | Start of Treatment up to 504 hours. |
| Time to maximum concentration (Tmax) of metformin after 3.5 days of treatment. | Start of Treatment up to 30 hours. |
| Area under the concentration versus time curve of HRS9531 from 0 to the time of the last measurable (positive) concentration (AUC0-t). | Start of Treatment up to 30 hours. |
| Area under the concentration versus time curve of HRS9531 from 0 to infinity (AUC0-inf). | Start of Treatment up to 504 hours. |
| Terminal half-life (t1/2) of HRS9531. | Start of Treatment up to 504 hours. |
| Clearance (CL/F) of HRS9531. | Start of Treatment up to 504 hours. |
| Apparent volume of distribution (VzF) of HRS9531. | Start of Treatment up to 504 hours. |
| Incidence and severity of adverse events. | Screening period up to 42 days. |
| Maximum concentration (Cmax) of HRS9531. | Start of Treatment up to 504 hours. |
Countries
China
Outcome results
None listed